Rectal Cancer Treatment (PDQ®)–Health Professional Version
SECTIONS
- General Information About Rectal Cancer
- Cellular Classification and Pathology of Rectal Cancer
- Stage Information for Rectal Cancer
- Treatment Option Overview for Rectal Cancer
- Stage 0 Rectal Cancer Treatment
- Stage I Rectal Cancer Treatment
- Stages II and III Rectal Cancer Treatment
- Stage IV and Recurrent Rectal Cancer Treatment
- Changes to This Summary (04/06/2018)
- About This PDQ Summary
- View All Sections
Changes to This Summary (04/06/2018)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to include pembrolizumab on the current list of active U.S. Food and Drug Administration-approved drugs that are used alone and in combination with other drugs for patients with metastatic colorectal cancer.
Added Pembrolizumab as a new subsection.
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
No hay comentarios:
Publicar un comentario